EBS
Emergent Biosolutions Inc
NYSE: EBS · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
$8.23
+3.00% today
Updated 2026-04-30
Market cap
$414.70M
P/E ratio
8.63
P/S ratio
0.56x
EPS (TTM)
$0.93
Dividend yield
—
52W range
$5 – $14
Volume
0.9M
Emergent Biosolutions Inc (EBS) Financial statements
SEC filings — annual and quarterly data.
Profit margin
7.08%
Operating margin
-15.20%
ROE
10.50%
ROA
5.34%
Debt/equity
1.14x
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2006 | $152.73M | $22.79M | 84.20% | 24.90% | 14.92% |
| 2007 | $182.91M | $22.94M | 77.96% | 18.09% | 12.54% |
| 2008 | $178.55M | $20.68M | 80.91% | 16.76% | 11.58% |
| 2009 | $234.79M | $31.14M | 80.30% | 17.10% | 13.26% |
| 2010 | $286.17M | $51.70M | 83.54% | 25.70% | 18.07% |
| 2011 | $273.38M | $23.02M | 84.57% | 11.74% | 8.42% |
| 2012 | $281.89M | $23.52M | 39.94% | 12.97% | 8.35% |
| 2013 | $312.75M | $31.14M | 41.79% | 13.69% | 9.96% |
| 2014 | $404.47M | $36.74M | 48.90% | 22.05% | 9.08% |
| 2015 | $489.33M | $62.87M | 55.69% | 28.92% | 12.85% |
| 2016 | $488.80M | $51.80M | 50.08% | 21.58% | 10.60% |
| 2017 | $560.90M | $82.60M | 50.56% | 22.16% | 14.73% |
| 2018 | $782.40M | $62.70M | 40.95% | 11.48% | 8.01% |
| 2019 | $1.11B | $54.50M | 43.68% | 10.32% | 4.93% |
| 2020 | $1.58B | $305.80M | 54.72% | 27.80% | 19.39% |
| 2021 | $1.77B | $219.50M | 44.72% | 19.25% | 12.38% |
| 2022 | $1.12B | $-223.80M | 38.11% | -14.81% | -19.97% |
| 2023 | $1.05B | $-760.50M | 34.31% | -69.23% | -72.48% |
| 2024 | $1.04B | $-190.60M | 35.97% | -10.42% | -18.26% |
| 2025 | $742.90M | $52.60M | 47.19% | 14.83% | 7.08% |